Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. http://globocan.iarc.fr. Accessed 26 Dec 2014.
Yang L, Parkin DM, Li L, Chen Y. Time trends in cancer mortality in China: 1987-1999. Int J Cancer. 2003;106:771–83.
Article
CAS
PubMed
Google Scholar
Chen WQ, Zheng RS, Zeng HM, Zou XN, Zhang SW, He J. [Report of cancer incidence and mortality in china, 2011] [in Chinese]. China Cancer. 2015;24:1–10.
Article
Google Scholar
Zur Hausen H. Papillomaviruses in human cancer. Appl Pathol. 1987;5:19–24.
CAS
PubMed
Google Scholar
Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518–27.
Article
PubMed
Google Scholar
Chen W, Zhang X, Molijn A, Jenkins D, Shi JF, Quint W, et al. Human papillomavirus type-distribution in cervical cancer in China: the importance of HPV 16 and 18. Cancer Causes Control. 2009;20:1705–13.
Article
PubMed
Google Scholar
Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374:301–14.
Article
CAS
PubMed
Google Scholar
Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367:1247–55.
Article
CAS
PubMed
Google Scholar
Zhu FC, Chen W, Hu YM, Hong Y, Li J, Zhang X, et al. Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18-25 years: results from a randomized controlled trial. Int J Cancer. 2014;135:2612–22.
Article
CAS
PubMed
PubMed Central
Google Scholar
ClinicalTrials.gov. http://www.clinicaltrials.gov. Accessed 21 Jan 2015.
Arie S. Global HPV, vaccination. BMJ. 2011;342:d1042.
Article
PubMed
Google Scholar
Jit M, Brisson M. Modelling the epidemiology of infectious diseases for decision analysis: a primer. Pharmacoeconomics. 2011;29:371–86.
Article
PubMed
Google Scholar
WHO position paper. http://www.who.int/immunization/documents/positionpapers/en/. Accessed 11 Jan 2016.
Brisson M, Edmunds WJ. Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs. Med Decis Making. 2006;26:434–46.
Article
CAS
PubMed
Google Scholar
Demarteau N, Detournay B, Tehard B, El Hasnaoui A, Standaert B. A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancer. Int J Public Health. 2011;56:153–62.
Article
PubMed
Google Scholar
Jit M, Demarteau N, Elbasha E, Ginsberg G, Kim J, Praditsitthikorn N, et al. Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models. BMC Med. 2011. doi:10.1186/1741-7015-9-54.
Google Scholar
Goldie SJ, O’Shea M, Campos NG, Diaz M, Sweet S, Kim SY. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Vaccine. 2008;26:4080–93.
Article
PubMed
Google Scholar
Jit M, Levin C, Brisson M, Levin A, Resch S, Berkhof J, et al. Economic analyses to support decisions about HPV vaccination in low- and middle-income countries: a consensus report and guide for analysis. BMC Med. 2013. doi:10.1186/1741-7015-11-23.
PubMed
PubMed Central
Google Scholar
Canfell K, Shi JF, Lew JB, Walker R, Zhao FH, Simonella L, et al. Prevention of cervical cancer in rural China: evaluation of HPV vaccination and primary HPV screening strategies. Vaccine. 2011;29:2487–94.
Article
PubMed
Google Scholar
Levin CE, Sharma M, Olson Z, Verguet S, Shi JF, Wang SM, et al. An extended cost-effectiveness analysis of publicly financed HPV vaccination to prevent cervical cancer in China. Vaccine. 2015;33:2830–41.
Article
PubMed
Google Scholar
Debicki D, Ferko N, Demarteau N, Gallivan S, Bauch C, Anonychuk A, et al. Comparison of detailed and succinct cohort modelling approaches in a multi-regional evaluation of cervical cancer vaccination. Vaccine. 2008;26 Suppl 5:F16–28.
Article
PubMed
Google Scholar
Konno R, Sasagawa T, Fukuda T, Van Kriekinge G, Demarteau N. Cost-effectiveness analysis of prophylactic cervical cancer vaccination in Japanese women. Int J Gynecol Cancer. 2010;20:385–92.
Article
PubMed
Google Scholar
National Bureau of Statistics of the People’s Republic of China. http://www.stats.gov.cn/tjsj/pcsj/rkpc/6rp/indexch.htm. Accessed 15 May 2013.
Jeffrey DS. Macroeconomics and health. Health: investing in health for economic development. 2001.
Google Scholar
Muñoz N. Progress in HPV vaccine introduction in Latin America. HPV TODAY. 2012. http://www.hpvtoday.com. Accessed 10 Dec 2014.
China National Plan for NCD Prevention and Treatment (2012-2015). http://www.chinacdc.cn/en/ne/201207/t20120725_64430.html. Accessed 12 Dec 2014.
China Guidelines for Pharmacoeconomic Evaluations. http://www.ispor.org/PEguidelines/source/China-Guidelines-for-Pharmacoeconomic-Evaluations_2011_Chinese.pdf. Accessed 20 May 2016.
National Bureau of Statistics of China. http://data.stats.gov.cn/easyquery.htm?cn=C01. Accessed 5 Jul 2014.
Shi JF, Chen JF, Canfell K, Feng XX, Ma JF, Zhang YZ, et al. Estimation of the costs of cervical cancer screening, diagnosis and treatment in rural Shanxi Province, China: a micro-costing study. BMC Health Serv Res. 2012. doi:10.1186/1472-6963-12-123.
Google Scholar
Zhao FH, Chen JF, Gao XH, Gao LM, Liu QG, Liu ZH, et al. [Effectiveness and health economic analysis of strategies on cervical cancer screening and early diagnosis and treatment] [in Chinsese]. Zhonghua Zhong Liu Za Zhi. 2012;34:632–6.
CAS
PubMed
Google Scholar
Shi JF, Canfell K, Lew JB, Zhao FH, Legood R, Ning Y, et al. Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China: an epidemiologic and cost-effectiveness modelling study. BMC Cancer. 2011;11:239.
Article
PubMed
PubMed Central
Google Scholar
Liu YJ, Zhang Q, Hu SY, Zhao FH. Costs of detection and treatment of cervical cancer, cervical intraepithelial neoplasias in China. Asia-Oceania Research Organisation in Genital Infection and Neoplasia (AOGIN) 2014, Beijing, China.
GAVI (Global Alliance for Vaccines and Immunisations). Human papillomavirus vaccine support; http://www.gavi.org/support/nvs/human-papillomavirus/. Accessed 20 Jun 2016.
PAHO (Pan American Health Organization). Expanded Program of Immunization Vaccine Prices for Year 2013- Amendment III.
Colombara DV, Wang SM. The impact of HPV vaccination delays in China: Lessons from HBV control programs. Vaccine 2013;31(38):4057–9. doi: 10.1016/j.vaccine.2013.06.031.
World Economic Outlook Database-April 2016, International Monetary Fund. http://www.imf.org/en/data. Accessed 12 Apr 2016.
Yu WZ, Yu JJ, Cui G, Jin SG, Wag J, Tao Z. [Study on the reasonable cost of national immunization program in some regions of china] [in Chinese]. Chinese JVaccines Immun. 2006;4:280–4.
Google Scholar
Suárez E, Smith JS, Bosch FX, Nieminen P, Chen CJ, Torvinen S, et al. Cost-effectiveness of vaccination against cervical cancer: a multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios. Vaccine. 2008;26 Suppl 5:F29–45.
Article
PubMed
Google Scholar
Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst. 2004;96(8):604–15.
Article
PubMed
Google Scholar
Gold MR, Franks P, McCoy KI, Fryback DG. Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care. 1998;36(6):778–92.
Article
CAS
PubMed
Google Scholar
Trogdon JG, Ekwueme DU, Subramanian S, Crouse W. Economies of scale in federally-funded state-organized public health programs: results from the National Breast and Cervical Cancer Early Detection Programs. Health Care Manag Sci. 2013;17(4):321–30.
Article
PubMed
Google Scholar
Vale DB, Morais SS, Pimenta AL, Zeferino LC. [Assessment of the cervical cancer screening in the Family Health Strategy in Amparo, Sao Paulo State, Brazil. Cad Saude Publica. 2010;26:383–90.
Article
PubMed
Google Scholar
Zhao FH, Lin MJ, Chen F, Hu SY, Zhang R, Belinson JL, et al. Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China. Lancet Oncol. 2010;11:1160–71.
Article
CAS
PubMed
Google Scholar
Moscicki AB, Hills N, Shiboski S, Powell K, Jay N, Hanson E, et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA. 2001;285:2995–3002.
Article
CAS
PubMed
Google Scholar
Van de Velde N. Brisson M, Boily MC, Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty. Am J Epidemiol. 2007;165:762–75.
Article
PubMed
Google Scholar
Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis. 2003;9:37–48.
Article
PubMed
PubMed Central
Google Scholar
Melnikow J, Nuovo J, Willan AR, Chan BK, Howell LP. Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol. 1998;92:727–35.
CAS
PubMed
Google Scholar
Quinn MA, Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman WT, et al. Carcinoma of the cervix uteri. Int J Gynaecol Obstet. 2006;95 Suppl 1:S43–103.
Article
PubMed
Google Scholar
Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsagué X, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13:89–99.
Article
CAS
PubMed
Google Scholar
Cagle AJ, Hu SY, Sellors JW, Bao YP, Lim JM, Li SM, et al. Use of an expanded gold standard to estimate the accuracy of colposcopy and visual inspection with acetic acid. Int J Cancer. 2010;126(1):156–61.
Article
CAS
PubMed
Google Scholar
Qiao YL, Sellors JW, Eder PS, Bao YP, Lim JM, Zhao FH, et al. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol. 2008;9(10):929–36.
Article
PubMed
Google Scholar
Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119:1095–101.
Article
CAS
PubMed
Google Scholar
Xu H, Zhao FH, Gao XH, Hu SY, Chen JF, Liu ZH, et al. [Cost-effectiveness analysis on the once in a life time cervical cancer screening program for women living in rural and urban areas of China] [in Chinese]. Zhonghua liu xing bing xue za zhi. 2013;34:399–403.
PubMed
Google Scholar
Li Q, Liu ZH, Liu ST, Li XL, Huang ME, Ye ML, et al. [Opportunistic Screening for cervical cancer in City Hospital] [in Chinese]. Chinese Cancer. 2008;17:176–8.
Google Scholar
Cancer, I.A.f.R.o. IARC handbooks of cancer prevention Vol. 10. Cervix cancer screening. Lyon: IARC Press; 2005.
Google Scholar
World Health Organization. WHO guide for standardization of economic evaluations of immunization programmes. 14th ed. Geneva: World Health Organization; 2008.
Google Scholar
Women’s health in rural China. Lancet. 2009;374:358.
National Health and Family Planning Commission of the People’s Republic of China. http://www.nhfpc.gov.cn/zwgkzt/pwstj/list.shtml Accessed 15 Oct 2014.
Shi JF, Canfell K, Lew JB, Qiao YL. The burden of cervical cancer in China: synthesis of the evidence. Int J Cancer. 2012;130:641–52.
Article
CAS
PubMed
Google Scholar
Ogembo JG, Manga S, Nulah K, Foglabenchi LH, Perlman S, Wamai RG, et al. Achieving high uptake of human papillomavirus vaccine in Cameroon: lessons learned in overcoming challenges. Vaccine. 2014;32:4399–403.
Article
PubMed
Google Scholar
Hariri S, Bennett NM, Niccolai LM, Schafer S, Park IU, Bloch KC. Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States - 2008-2012. Vaccine. 2015;33:1608–13.
Article
PubMed
Google Scholar
Goldie SJ, O’Shea M, Diaz M, Kim SY. Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications. Reprod Health Matters. 2008;16(32):86–96.
Article
PubMed
Google Scholar
Levin A, Wang SA, Levin C, Tsu V, Hutubessy R. Costs of introducing and delivering HPV vaccines in Low and lower middle income countries: inputs for GAVI policy on introduction grant support to countries. PLoS One. 2014. doi:10.1371/journal.pone.0101114.
Google Scholar
Lieu TA, Ray GT, Black SB, Butler JC, Klein JO, Breiman RF, et al. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. JAMA. 2000;283(11):1460–8.
Article
CAS
PubMed
Google Scholar
Kim JJ, Sharma M, O’Shea M, Sweet S, Diaz M, Sancho-Garnier H, et al. Model-based impact and cost-effectiveness of cervical cancer preventionin the Extended Middle East and North Africa (EMENA). Vaccine. 2013;31 Suppl 6:G65–77.
Article
PubMed
Google Scholar
Jit M, Brisson M, Portnoy A, Hutubessy R. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study. Lancet Glob Health. 2014. doi:10.1016/S2214-109X(14)70237-2.
Google Scholar
Fesenfeld M, Hutubessy R, Jit M. Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: a systematic review. Vaccine. 2013;31(37):3786–804.
Article
PubMed
Google Scholar
Vokó Z, Nagyjánosi L, Kaló Z. Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary. BMC Public Health. 2012. doi:10.1186/1471-2458-12-924.
PubMed
PubMed Central
Google Scholar
Kim JJ, Campos NG, O’Shea M, Diaz M, Mutyaba I. Model-based impact and cost-effectiveness of cervical cancer prevention in sub-saharan Africa. Vaccine. 2013;31 Suppl 5:F60–72.
Article
PubMed
Google Scholar
UNICEF At a glance: Panama. Panama first in region to provide free HPV vaccine to young adolescent girls. http://www.unicef.org/infobycountry/panama_46169.html. Accessed 17 Oct 2014.
UNICEF Annual Report 2013 - Sierra Leone. http://www.unicef.org/about/annualreport/files/Sierra_Leone_COAR_2013.pdf. Accessed 17 Oct 2014.
UNICEF Annual Report 2012-Tanzania. http://www.unicef.org/tanzania/TCO_Annual_Report_2012_-_FINAL_June_18_2013.pdf. Accessed 17 Oct 2014.
Zhang SK, Pan XF, Wang SM, Yang CX, Gao XH, Wang ZZ, et al. Perceptions and acceptability of HPV vaccination among parents of young adolescents: A multicenter national survey in China. Vaccine. 2013;31:3244–9.
Article
PubMed
Google Scholar
Zhao FH, Tiggelaar SM, Hu SY, Zhao N, Hong Y, Niyazi M, et al. A multi-center survey of HPV knowledge and attitudes toward HPV vaccination among women, government officials, and medical personnel in China. Asian Pac J Cancer Prev. 2012;13:2369–78.
Article
PubMed
Google Scholar
Wang SM, Zhang SK, Pan XF, Ren ZF, Yang CX, Wang ZZ, et al. Human papillomavirus vaccine awareness, acceptability, and decision-making factors among Chinese college students. Asian Pac J Cancer Prev. 2014;15:3239–45.
Article
PubMed
Google Scholar
Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis. 2007;13:28–41.
Article
PubMed
PubMed Central
Google Scholar
Stanley M, Lowy DR, Frazer I. Chapter 12: Prophylactic HPV vaccines: underlying mechanisms. Vaccine. 2006;24 Suppl 3:S3/106–13.
CAS
Google Scholar
Gaudet M, Hamm J, Aquino-Parsons C. Incidence of ano-genital and head and neck malignancies in women with a previous diagnosis of cervical intraepithelial neoplasia. Gynecol Oncol. 2014;134:523–6.
Article
PubMed
Google Scholar
Sathish N, Wang X, Yuan Y. Human papillomavirus (HPV)-associated oral cancers and treatment strategies. J Dent Res. 2014;93(7 suppl):29S–36.
Article
CAS
PubMed
PubMed Central
Google Scholar
Nygård M, Hansen BT, Dillner J, Munk C, Oddsson K, Tryggvadottir L, et al. Targeting human papillomavirus to reduce the burden of cervical, vulvar and vaginal cancerand pre-invasive neoplasia: establishing the baseline for surveillance. PLoS One. 2014. doi:10.1371/journal.pone.0088323.
Google Scholar